These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33269711)

  • 1. [Recurrence and progression after BCG.].
    Lendínez-Cano G; Rivero-Belenchón I; Medina-López RA
    Arch Esp Urol; 2020 Dec; 73(10):929-933. PubMed ID: 33269711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatments in BCG failure. Where do we stand today?
    Fragkoulis C; Glykas I; Bamias A; Stathouros G; Papadopoulos G; Ntoumas K
    Arch Esp Urol; 2021 Sep; 74(7):681-691. PubMed ID: 34472437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune therapies in non-muscle invasive bladder cancer.
    Ho PL; Williams SB; Kamat AM
    Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-muscle invasive bladder cancer].
    Irani J
    Rev Prat; 2014 Dec; 64(10):1382-5. PubMed ID: 25665317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [When the conservative treatment in high-risk non-muscle invasive bladder cancer patients should be abandoned].
    Colombo R; Maccagnano C; Rocchini L; Pellucchi F
    Urologia; 2013; 80 Suppl 21():48-52. PubMed ID: 23559131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of visible diffuse peritoneal Bacillus Calmette-Guérin infection at the time of planned radical cystectomy.
    Nielsen MØ; Elversang J; Martin Poulsen A; Persson Theilgaard Z; Joensen UN
    Scand J Urol; 2021 Dec; 55(6):505-506. PubMed ID: 34470576
    [No Abstract]   [Full Text] [Related]  

  • 15. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
    Hassler MR; Shariat SF; Soria F
    Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guérin (Danish 1331 strain).
    Kulkarni JN; Gupta R
    BJU Int; 2002 Oct; 90(6):554-7. PubMed ID: 12230616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer].
    Kramer MW; Gakis G
    Urologe A; 2020 Jul; 59(7):784-789. PubMed ID: 32468091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
    Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.